Mukoviszidose Institut gGmbH, Bonn, Germany.
J Cyst Fibros. 2011 Jun;10 Suppl 2:S110-3. doi: 10.1016/S1569-1993(11)60016-7.
Workpackage 4 of EuroCareCF brought together a group of small and middle-size companies (SMEs) with strong interest in drug development for cystic fibrosis (CF). The common interest of SMEs and patient organizations (PO) in mutually beneficial cooperation was assessed. This was achieved by identifying critical unmet medical needs of CF patients and by analyzing fields of cooperation between SMEs and POs.
Over and above all, finding a cure for the disease is considered the most important unmet medical need by POs. However, preventing or slowing down any further deterioration of health and the alleviation of symptoms are also considered valuable objectives. Areas of co-operation with SMEs include the preparation and conduct of clinical trials and co-operation in the post-marketing authorization period.
If a policy of transparency and respect for the independence of POs is applied, SMEs and POs can develop mutually beneficial and sustainable co-operation.
EuroCareCF 的第 4 工作包汇集了一批对囊性纤维化 (CF) 药物开发有浓厚兴趣的中小企业 (SMEs)。评估了中小企业和患者组织 (PO) 在互利合作方面的共同利益。这是通过确定 CF 患者未满足的关键医疗需求以及分析中小企业和 PO 之间的合作领域来实现的。
除其他外，PO 认为找到治愈疾病的方法是最重要的未满足医疗需求。然而，预防或减缓任何进一步的健康恶化和症状缓解也被认为是有价值的目标。与中小企业合作的领域包括临床试验的准备和进行以及上市后授权期间的合作。
如果采用透明和尊重 PO 独立性的政策，中小企业和 PO 可以发展互利和可持续的合作。
